Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initiation of agomelatine after prior antidepressant treatment in outpatients with major depressive disorder
ISRCTN97599615Phase 3Completed
- Sponsor
- Servier
- Start
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Total number of discontinuation emergent symptoms. Started Nov 2010; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN97599615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97599615.